Piramal Pharma profitability ratios
Per cent unless marked ×
| Tap a line for its trend | Last 12Mto Sep 2026 | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
Returns | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |||||
|---|---|---|---|---|---|---|
| −4.0% | −4.0% | 1.1% | 0.2% | −2.8% | ||
| −1.9% | −1.9% | 0.6% | 0.1% | −1.4% | ||
| 0.7% | 0.7% | 5.5% | 4.2% | −0.5% | ||
| 2.4% | 0.7% | 2.0% | 1.5% | −0.4% | ||
Margins | ||||||
| 12.3% | 10.4% | 15.8% | 14.6% | 8.9% | ||
| 1.0% | 1.0% | 6.9% | 5.6% | −0.7% | ||
| — | 190.8% | 17.6% | 46.3% | — | ||
| −0.4% | −2.6% | 3.7% | 1.5% | −2.5% | ||
| −2.1% | −3.7% | 1.0% | 0.2% | −2.6% | ||
| −2.1% | −3.7% | 1.0% | — | — | ||
| 8.6% | 8.6% | 2.5% | 3.6% | −6.8% | ||
Additional | ||||||
| −615.3% | −64.3% | 94.7% | 134.8% | −38.0% | ||
| — | −5.7% | 15.9% | 0.0% | −35.9% | ||
| −4.0% | −4.2% | 1.0% | 0.2% | −3.8% | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.